Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome (NCT00077116)
Drugs used in chemotherapy, such as Idarubicin (Idamycin®; Pfitzer, Inc.) and cytarabine (DepoCyt®; Sigma Tau Pharmaceuticals), work in different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies, including the antibody-drug conjugates or ADCs such as gemtuzumab ozogamicin (Mylotarg®; Pfizer/Wyeth-Ayerst Laboratories), can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
Giving monoclonal antibody therapy together with chemotherapy may kill more cancer cells. Giving healthy stem cells from a donor whose blood closely resembles the patient’s blood will help the patient’s bone marrow make new stem cells that become red blood cells, white blood cells, and platelets.
This phase II trial is studying how well giving idarubicin and cytarabine together with gemtuzumab ozogamicin works in treating patients with previously untreated high-risk myelodysplastic syndrome or acute myeloid leukemia secondary to myelodysplastic syndrome.
This trial is sponsored by European Organisation for Research and Treatment of Cancer (EORTC). 
- Myelodysplastic Syndromes
- Drugs used in this trial
- Procedure: allogeneic bone marrow transplantation
- Procedure: peripheral blood stem cell transplantation
- Radiation: radiation therapy
- Phase: II
- Enrollment: 31
- Start: November 2003
- Primary Completion: November 2006
- Last verified: July 2012
Last Editorial review: July 22, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.